Gynecological Cancers Therapeutics

Gynecological Cancers Therapeutics

Gynecological cancer is a branch of oncology where cancer develops in the reproductive areas of a woman including the cervix, endometrium, fallopian tubes, ovaries, uterus, vagina, and vulva. Gynecological cancers most often begin in the flat squamous cells that line the inside of the cervical, uterine, or vaginal region. Gynecological cancers can develop from infection with cancer-causing viruses types like human papillomavirus (HPV), especially HPV type 16, occupational exposure to asbestos and synthetic fibers, epstein-barr virus infection, genetic disorders, rising cases of obesity, rising demand for oral drugs, increasing geriatric population which provides propelling force to the gynecological cancers therapeutics market. For instance, as per the Centers for Disease Control and Prevention, in the U.S., increasing age poses a high risk of developing gynecological cancers in most women. It has been estimated that each year in the U.S., about 71,500 new cases of gynecological cancers are diagnosed, including cervical, ovarian, uterine, vaginal, and vulvar cancers. Several factors, including a surge in the incidence of gynecological cancers, increasing awareness regarding gynecological cancers, increasing smoking population, rising alcoholism culture, and increased investments from the government, public, and private sectors in oncology departments are driving the growth of the market during the forecast period.

The Gynecological Cancers Therapeutics Market is expected to grow at a steady rate of around 6.5% owing to the increased prevalence of immune system deficiency globally due to prevalent unhealthy lifestyles. For instance, according to the BMC Public Health, in July 2023, the prevalence of unhealthy lifestyles was 86.4% for diet, 14.5% for alcohol, 6.0% for tobacco, 72.2% for physical activity, 42.3% for screen time, and 63.9% for sleep duration. According to the 2021 National Survey on Drug Use and Health (NSDUH), 29.5 million people ages 12 and older had an Alcohol Use Disorder (AUD) in the year 2020. Several other factors, such as rising genetic disorders and unhealthy lifestyles are leading drivers of gynecological cancers’ therapeutics globally. Apart from this, accelerated treatment efficiency with gynecological cancer therapeutics has resulted in faster treatment procedures and better accuracy which is also driving this market of gynecological cancer therapeutics at a steady rate. Many new therapies are being introduced for treating these cancers including a combination of treatments, immunotherapy, and many more. For instance, on July 2023, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary advanced or recurrent endometrial cancer (EC) that is mismatch repair deficient (dMMR), as determined by an FDA-approved test.

• Based on cancer type, the market is segmented into cervical cancer, uterine cancer, ovarian cancer, and others. The cervical cancer segment held the maximum share in the global market of gynecological cancer therapeutics in 2022. This segment dominated the market because of the increased prevalence of ill lifestyles including smoking, alcoholism, and unhealthy diet among people. Cervical cancers are basically squamous cell carcinomas, originating from the skin of the cervix. Human papillomavirus (HPV) which is an extremely common virus transmitted through sexual contact is also a major causative agent for cervical cancer. Two human papillomavirus (HPV)- type 16 and type 18 are responsible for nearly 50% of high-grade cervical pre-cancers. According to the World Health Organization, about 99% of cervical cancer cases are associated with infection with HPV in 2022. Increased exposure to toxic substances and chemicals causing chemical carcinogenesis is also a propelling factor for this segment. Thus, amongst cancer types, cervical cancer held a significant share of the market in 2022.
• Based on treatment type, the market is categorized into chemotherapy, targeted therapy, and others. The targeted therapy segment is expected to hold a significant share of the market in the forecast period owing to its potential feature of helping the immune system destroy cancer cells. Targeted therapy enhances the body’s immune system to identify and kill cancerous cells. Conventional methods like surgery cannot be effective in treating gynecological cancers, in this case, targeted therapy shows promising results. In recent years, there has been a surge in the approval of various immunomodulators. For instance, immunomodulator Pembrolizumab (Keytruda) by Merck KGaA., got FDA approval on January 2023. Also, Dostarlimab (Jemperli) by immunomodulator GlaxoSmithKline plc got FDA approval in February 2023. Thus, amongst treatment types, the targeted therapy category is expected to witness higher CAGR during the forecast period.
• On the basis of distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held a significant share of the market in 2022 attributed to the rising admissions in hospitals for cancer treatments, rising government support, increasing grants by pharmaceutical companies, and awareness programs regarding safety measures in the past few years. For instance, as per the National Library of Medicine in June 2021, 63,926 patients with cervical cancer were admitted to 47 hospitals across mainland China. Thus, amongst distribution channels, hospital pharmacies held a significant share of the market in 2022.
• For a better understanding of the market adoption of gynecological cancers therapeutics, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with a high CAGR in the global gynecological cancers therapeutics market in the forecast period. Several factors such as a surge in the geriatric population in the region, development of a wide range of therapeutics for gynecological cancer treatment, enhanced accessibility, and diversified healthcare costs are driving the market’s growth during the forecast period. Further, the increase in incidences of gynecological cancers, the presence of key generic pharmaceutical companies in the region, and the surge in government initiatives and special communities are also having a positive impact on the market’s growth. There have been significant improvisations and enhancements in gynecological cancer therapeutics in the region. For instance, according to the National Institute of Health in 2022, there were approximately 4,820,000 and 2,370,000 new cancer cases in China. Thus, amongst regions, APAC is expected to witness higher CAGR during the forecast period.
• Some of the major players operating in the market include Amgen Inc.; AstraZeneca; AbbVie Inc.; Bristol Myers Squibb Company; GSK plc.; Lilly; Merck KGaA; Pfizer Inc.; Novartis AG; and Sanofi.